AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Syndax Pharmaceuticals, Inc.
Video analysis: SNDX
All videosNo video analysis for this stock yet. Request one from our team.
News: SNDX
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax Announces Participation in September Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.
BlackRock Inc. Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX
BlackRock Inc. bought a new position in Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) in the undefined quarter, according to its most recent disclosure with the SEC. The firm bought 9,020,006 shares of the company's stock, valued at approximately $197,177,000. BlackRock Inc. owned 10.18% of Syndax Pharmaceuticals at the end of the most recent quarter.
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying about 410% upside from the price used in Citi's call, while his $57 Syndax Pharmaceuticals target points to roughly 190%.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Syndax Pharmaceuticals Q2 Earnings Call Highlights
Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow.
